Publication List: Recent Fortrea Publications about Antibody-Drug Conjugates 

Antibody-drug conjugates (ADCs) represent one of the largest growth segments in oncology, holding the promise of more effective therapies that can offer lower systemic toxicity, for better patient outcomes.- Download this list of our top three recent publications about ADCs to learn more about how Fortrea oncologists are collaborating with others in the industry to accelerate advancements in ADC trial design.

Article: Advance your antibody-drug conjugate pipeline with our experience and expertise

ADCs are driving advances in oncology therapies, with more than a dozen treatments approved by the FDA and many more in the pipeline. Download our infographic that summarizes ADCs in the industry plus our experience in supporting clinical trials of ADCs.

Case Study: Pediatric Oncology Rare Disease Trial

Download this case study that discusses the challenges of conducting a pediatric rare disease trial across several regions globally. In this trial, pediatric patients with a specific type of solid tumor and a rare genetic mutation were studied. Adding to the challenge were COVID-19-related site closures and restrictions. While work continues, the first two cohorts are fully enrolled and the program is on track!

Publication List: Recent Fortrea Immuno-oncology Publications

Immuno-oncology therapies, also known as cancer immunotherapies, represent a broad class of treatments such as targeted antibodies, tumor-infecting viruses, checkpoint inhibitors and cancer vaccines. The many types of therapeutic agents have been under study for decades and Fortrea has participated in over 290 immuno-oncology trials in just the last five years (2019-2023).

Recent Webinar

Accelerating Clinical Development through Design, Diversity & Digitalization in Oncology and Beyond

This dynamic panel-format webinar will explore how to speed drug development and improve return on investment (ROI) by adopting a “3-D” approach to trials focusing on Design, Diversity, and Digitalization. Oncology trials will be the focal point for our discussions, but the key insights are applicable to a wide range of therapeutic areas. The need to improve geographical, racial, ethnic, and other forms of diversity and inclusion in trials –including new legislation and regulatory guidance documents to spur adoption of diverse trials - has been at the forefront for several years. Insights will be shared on what has worked and what still needs to be done, and how new tools, digital and mobile health and other innovative approaches can lead the way.
With so many recent advances in applying “big data” strategies and Artificial Intelligence to trial design and execution, the speakers will discuss concrete ways these novel approaches have impacted trials and pipelines. Case studies and aggregate insights will be reviewed with an eye towards improving trial outcomes and performance against KPIs.

Enabling sites to do what sites do best

Fortrea places Sites and investigators at the forefront of trial planning and operations, working together to strengthen trial delivery and expand healthcare options for all.